2023-12-24 17:53:00
The Medicines and Health Products Safety Agency reported the December 22 a supply voltage concerning the Ixiaro vaccine (Valneva laboratory). This vaccine is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants over 2 months of age. The administration of Ixiaro should be considered in subjects exposed to a risk of infection by the virus during travel or in the context of their professional activity.
- Closure of the city canal
- Hospital channel quota.
- Emergency stock: in situations where a primary vaccination schedule has already been initiated (patient waiting for the 2nd injection) an emergency emergency stock for pharmacies is constituted. In this context, the Valneva laboratory specifies that it is possible to contact its CSP depositary directly via the address Commande_adv@movianto.com, specifying the context of the order (see situations stated above).
- Normal delivery planned for the end of March 2024.
In order to secure the situation in France as much as possible and to preserve available stocks, the sale and export of the medicine by wholesale distributors abroad is prohibited from the publication of this information sheet on the website of the National Agency for the Safety of Medicines and Health Products (ANSM), in application of public health law 2016-41 published in the Official Journal on January 27, 2016 and the provisions of articles L.5121-30 and L.5124 -17-3 of the Public Health Code. This measure prohibiting sales outside the national territory, or to wholesale distributors for export, must be applied and respected until the medicine is made available normally, allowing a continuous and appropriate supply to the national market.
Source: National Agency for Medicines and Health Products (ANSM).
1703470374
#Supply #tension #Ixiaro #vaccine